This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, B. Articles by Gelman, I. H. Search for Related Content PubMed PubMed Citation Articles by Su, B. Articles by Gelman, I. H.

SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor Inhibition

Departments of ¹ Cancer Genetics, and ² Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Irwin H. Gelman, Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-7681; Fax: 716-845-2342; E-mail: Irwin.gelman{at}roswellpark.org.

SSeCKS, a Src-suppressed protein kinase C substrate with metastasis suppressor activity, is the rodent orthologue of human gravin/AKAP12, a scaffolding protein for protein kinase A and protein kinase C. We show here that the tetracycline-regulated reexpression of SSeCKS in MatLyLu (MLL) prostate cancer cells suppressed formation of macroscopic lung metastases in both spontaneous and experimental models of in vivo metastasis while having minimal inhibitory effects on the growth of primary-site s.c. tumors. SSeCKS decreased angiogenesis in vitro and in vivo by suppressing vascular endothelial growth factor (VEGF) expression in MLL tumor cells as well as in stromal cells. The forced reexpression of VEGF₁₆₅ and VEGF₁₂₁ isoforms was sufficient to reverse aspects of SSeCKS metastasis-suppressor activity in both the experimental and spontaneous models. SSeCKS reexpression in MLL cells resulted in the down-regulation of proangiogenic genes, such as osteopontin, tenascin C, KGF, angiopoietin, HIF-1, and PDGFRß, and the up-regulation of antiangiogenic genes, such as vasostatin and collagen 18a1, a precursor of endostatin. These results suggest that SSeCKS suppresses formation of metastatic lesions by inhibiting VEGF expression and by inducing soluble antiangiogenic factors. (Cancer Res 2006; 66(11): 5599-607)

This article has been cited by other articles:

				S. Akakura, C. Huang, P. J. Nelson, B. Foster, and I. H. Gelman Loss of the ssecks/gravin/akap12 Gene Results in Prostatic Hyperplasia Cancer Res., July 1, 2008; 68(13): 5096 - 5103. [Abstract] [Full Text] [PDF]

				M. Tessema, R. Willink, K. Do, Y. Y. Yu, W. Yu, E. O. Machida, M. Brock, L. Van Neste, C. A. Stidley, S. B. Baylin, et al. Promoter Methylation of Genes in and around the Candidate Lung Cancer Susceptibility Locus 6q23-25 Cancer Res., March 15, 2008; 68(6): 1707 - 1714. [Abstract] [Full Text] [PDF]

				Y. Bu and I. H. Gelman v-Src-mediated Down-regulation of SSeCKS Metastasis Suppressor Gene Promoter by the Recruitment of HDAC1 into a USF1-Sp1-Sp3 Complex J. Biol. Chem., September 14, 2007; 282(37): 26725 - 26739. [Abstract] [Full Text] [PDF]